Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Ibandronate

Known as: (1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate, 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate 
A synthetic nitrogen-containing bisphosphonate. Ibandronate inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Approximately 10 million men and women in the U.S. have osteoporosis,1 a metabolic bone disease characterized by low bone density… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2017
Review
2017
BACKGROUND Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2007
Review
2007
SummaryBisphosphonates (BPs) are well established as the leading drugs for the treatment of osteoporosis. There is new knowledge… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Once‐monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3‐year vertebral fracture risk reduction: 52%) oral ibandronate regimens… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Oral daily (2.5 mg) and intermittent ibandronate (between‐dose interval of >2 months), delivering a similar cumulative exposure… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Although intravenous (i.v.) bisphosphonates are the standard of care for metastatic bone disease, they are less than ideal for… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with placebo as intravenous… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Abstract—The present experiments were carried out to test the hypothesis that artery calcification is linked to bone resorption… Expand
  • figure 1
  • table 1
  • figure 4
  • figure 3
  • table I
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Bisphosphonates are currently the most important class of antiresorptive drugs used for the treatment of metabolic bone diseases… Expand
Is this relevant?